Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + leucovorin + oxaliplatin (Instituto do Câncer do Estado de São Paulo)
- Development stage
- Phase 4
- Lead developer
- Instituto do Cancer do Estado de São Paulo
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
mFLOX is a modified chemotherapy regimen consisting of bolus fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. It is a variation of the standard FLOX regimen, utilizing a significantly lower dose of leucovorin to reduce treatment costs and improve accessibility, particularly in resource-limited settings. The regimen is administered intravenously without the need for an infusion pump, making it a convenient alternative to infusional regimens like FOLFOX or FOLFIRINOX. mFLOX is primarily used as a first-line treatment for patients with metastatic colorectal cancer (mCRC) and is being evaluated in clinical trials for patients with unresectable or metastatic pancreatic adenocarcinoma who are ineligible for infusional FOLFIRINOX.
- Other names
- mFLOXmFLOX regimenmodified FLOXmodified FLOX regimen
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + leucovorin + oxaliplatin (Instituto do Câncer do Estado de São Paulo).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + leucovorin + oxaliplatin (Instituto do Câncer do Estado de São Paulo).